Skip to content

    Fairchem Organic

    FAIRCHEMOR
    Chemicals·30 May 2025
    Management Summary

    Fairchem Organics reported Q4 FY25 revenue of ₹121 crores, up 6.3% QoQ, but EBITDA margins compressed to 3.64% due to a 22% additional custom duty on a key raw material and pricing pressure from Chinese competitors. Despite these challenges, the company achieved over 11% volume growth QoQ and is making progress on its high-value Isostearic acid product, securing 16 customer approvals. New product development is underway, with equipment expected by December 2025 and trials starting in early 2026, utilizing 40,000 tons of earmarked capacity.

    Highlights

    5
    • Q4 volumes increased by greater than 11% on a quarter-to-quarter basis.

    • Q4 value growth achieved of greater than 6% on a quarter-to-quarter basis.

    • Isostearic acid volumes increased compared to last financial year.

    • Around 16 customer approvals received for Isostearic acid, with commercial orders already started.

    • Earmarked 40,000 tons (1/3rd of 120,000 MTPA raw material throughput) capacity for new products.

    Concerns

    5
    • EBITDA margins declined to 3.64% mainly due to relatively higher raw material cost as a percentage of sales.

    • 22% additional custom duty imposed on key raw material (dimer fatty acid) since September 14, 2024, leading to sharp cost escalation.

    • Inability to pass on cost burden to customers due to pricing pressure from Chinese competitors.

    • Paint industry demand expected to be soft during the monsoon period, with revival anticipated in Oct-Dec.

    • Management refused to disclose Isostearic acid margin profile, citing business secrets.

    What Changed2

    vs Q1 FY26

    Guidance items2 → 7 (+5)Risks discussed4 → 5 (+1)
    Key financials

    Metrics

    9

    Periods

    2

    Q4

    4
    • Revenue from Operations
      ₹121 Cr
      YoY-25%QoQ+6.3%
    • EBITDA
      ₹4 Cr
    • EBITDA Margin
      3.6%
    • Net Profit After Tax
      ₹0.6 Cr

    FY25

    5
    • Revenue from Operations
      ₹538 Cr
    • EBITDA
      ₹43 Cr
    • EBITDA Margin
      8.0%
    • Net Profit After Tax
      ₹22 Cr
    • Profit Margin
      4.1%

    Guidance & targets

    7
    CategoryTargetPriority
    Capacity Utilization
    Isostearic Acid Capacity Utilization
    Higher capacity utilization
    Medium
    Capacity Utilization
    Isostearic Acid Optimum Utilization
    Optimum utilization
    High
    Volume Growth
    Isostearic Acid Pick-up
    Further pick up
    Medium
    New Product Development
    New Product Equipment Delivery
    Equipment received
    High
    New Product Development
    New Product Trials Start
    Trials start
    High
    Capacity Allocation
    New Product Capacity
    40,000 tons
    High
    Approvals
    Isostearic Acid Approvals
    All approvals
    High

    Isostearic Acid Volume Pick-up

    H1 FY26
    CurrentGradually picking up, increased volumes vs last FY
    TargetFurther pick-up in H1 FY26

    Why it matters

    Key to improving overall profitability and leveraging new product capacity, indicating market acceptance and ramp-up progress.

    Isostearic acid is gradually picking up. It will take further 6 months. In the first half of this financial year, it would pick up compared to the previous 6 months. And again, in the second half of this current financial year, it will further pick up.

    How to verify

    guidance_and_targets[category='Volume Growth'][metric='Isostearic Acid Pick-up']

    Risks & concerns

    5
    RiskSeverity

    High Raw Material Costs due to Custom Duty

    22% additional custom duty on dimer fatty acid since Sep 14, 2024, leading to sharp cost escalation and EBITDA margin compression.Management acknowledged

    high

    Competition from Chinese Manufacturers

    Chinese competitors are not subjected to similar additional custom duties, leading to pricing pressure and inability to pass on increased costs.Management acknowledged

    medium

    Slow Government Response to Policy Issues

    Representation made to the government for increased custom duty on raw material is unlikely to yield quick results due to the company being a sole manufacturer.Management downplayed

    medium

    Demand Cyclicality in End-User Industries (Paint Sector)

    Paint industry demand is seasonal, with a slowdown during the monsoon period, impacting sales, though recovery is expected Oct-Dec.Management acknowledged

    medium

    Long Approval Cycles for Specialty Products (Isostearic Acid)

    Trials and approvals for Isostearic acid in the cosmetics industry take a long time, delaying optimal utilization, though it also creates high entry barriers.Management acknowledged

    medium

    Q&A highlights

    7

    “Being the only player in India, it is really tough. We are trying our best, but I cannot say when it will happen... it is highly unlikely that our sole request may receive substantial attention from the government.”

    Highlights the company's vulnerability to government policy and lack of industry support for duty reversal, impacting raw material costs and competitive position.

    asked by Shivam Parekh

    2 min read5 chapters

    Detailed Narrative

    01

    Q4 FY25 Performance and Margin Compression

    Fairchem Organics reported Q4 FY25 revenue from operations at ₹121 crores, marking a 6.3% sequential increase but a 25% year-on-year decrease. Despite volume growth exceeding 11% and value growth over 6% quarter-on-quarter, EBITDA margins compressed significantly to 3.64%, resulting in a net profit after tax of approximately ₹60 lakhs. The full fiscal year FY25 saw revenues of ₹538 crores and an EBITDA margin of 7.96%, with a net profit of ₹22 crores and a profit margin of 4.09%.

    02

    Impact of Custom Duties and Chinese Competition

    A major challenge impacting profitability is the 22% additional custom duty imposed on dimer fatty acid, a key raw material, effective September 14, 2024. This duty has sharply escalated costs, which the company has been unable to pass on to customers due to intense pricing pressure from Chinese competitors who are not subject to similar tariffs. Management is exploring new raw materials, energy saving, and yield improvement initiatives to mitigate this cost burden.

    03

    Progress on High-Value Isostearic Acid

    The company is making steady progress with its high-value Isostearic acid product, reporting increased volumes compared to the last financial year. Management expects a further pick-up in the first half of FY26, with optimum utilization targeted by FY27. Around 16 customer approvals have been secured, and commercial orders have already begun, indicating a positive market reception despite the long approval cycles inherent in the cosmetics industry.

    04

    New Product Development and Capacity Allocation

    Fairchem Organics is actively developing new products, with equipment for a small-quantity plant ordered and expected to arrive within six months, by December 2025. Trials for these new products are slated to begin in the January-March 2026 period. The company has earmarked 40,000 tons of its 120,000 metric tons per annum raw material throughput capacity for these new offerings, signaling a strategic shift towards product diversification.

    05

    Paint Industry Outlook and Demand Cyclicality

    While sales to the paint industry, a significant end-user, have seen a slight decline, management remains 'fairly comfortable💬' due to the unique nature of their product. However, a broader revival in paint industry demand is anticipated only in the October-December quarter, following the typical monsoon-induced slowdown. The company acknowledges that a sustained recovery depends on the real estate sector's performance.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.